

A Comprehensive Review on the Assessment of the Treatment of Cerebral Palsy in Patients with Cerebral Palsy

Kabra Vinay S*, Gaikwad Rohan D, Padole Rushikesh G, Kapse (Yalam) Vidya and Dharashive VM

Pharmacy Practice Department, Shivlingeshwar College of Pharmacy, Almala, Ausa, Latur, Maharashtra, India

***Corresponding Author:** Kabra Vinay S, Pharmacy Practice Department, Shivlingeshwar College of Pharmacy, Almala, Ausa, Latur, Maharashtra, India.

Received: April 09, 2025; **Published:** April 29, 2025

Abstract

Cerebral palsy (CP) is a complex neurological disorder affecting movement, muscle tone, and posture due to brain abnormalities that occur before, during, or shortly after birth. Treatment strategies, including pharmacological, therapeutic, and surgical interventions, aim to enhance motor function and overall quality of life. Assessing the efficacy of these interventions is essential to optimizing patient outcomes. This review provides a comprehensive analysis of treatment modalities, discusses assessment methodologies, and explores emerging advancements such as gene therapy, artificial intelligence, and robotics in rehabilitation.

The current body of research underscores the importance of a multidisciplinary approach tailored to the unique needs of each CP patient. This paper delves into various pharmacological agents used for spasticity and pain management, the significance of physical and occupational therapies, and the effectiveness of surgical interventions. Additionally, complementary and alternative therapies such as acupuncture and hydrotherapy are examined for their potential benefits. The review concludes with insights into future research directions, emphasizing the role of precision medicine and technological innovations in advancing CP treatment paradigms [4,11,12,14,15].

Keywords: Cerebral Palsy; Treatment Evaluation; Rehabilitation; Spasticity Management; Neurological Disorders

Introduction

Cerebral palsy (CP) is a non-progressive neurological disorder resulting from damage to the developing brain, affecting movement and muscle coordination. It remains the most prevalent childhood motor disability, affecting approximately 2 to 3 per 1,000 live births globally, with prevalence rates varying across different populations and healthcare settings. CP primarily results from prenatal, perinatal, or postnatal brain injuries that interfere with normal motor function, leading to spasticity, muscle weakness, impaired coordination, and involuntary movements. The severity and functional impact of CP range widely, with some individuals experiencing mild motor impairments while others require comprehensive lifelong care. Cerebral palsy (CP) is one of the most common childhood neurological disorders worldwide, including in India. The prevalence of CP in India varies due to differences in diagnostic criteria, availability of healthcare, and regional disparities. According to recent estimates, the prevalence of CP in India ranges from 1.5 to 4 cases per 1,000 live births. Urban hospital-based studies often report higher numbers due to increased awareness and access to diagnostics, whereas rural areas may underreport cases due to limited healthcare infrastructure [1,3,7,6,10].

In a systematic review and meta-analysis by Arora, *et al.* (2020), the pooled prevalence of CP among Indian children was found to be approximately 2.95 per 1,000 live births. This rate aligns closely with global estimates but highlights a notable burden on pediatric neurology services across the country. Furthermore, studies from tertiary care hospitals in Gujarat, Maharashtra, and Kerala have reported prevalence rates between 2.1 and 3.6 per 1,000 children, emphasizing regional variability.

When focusing on children under the age of 18 years, CP accounts for a significant proportion of pediatric disability cases. Approximately 85% of CP cases in India are diagnosed before the age of 5, and most children remain dependent on caregivers for daily activities throughout adolescence. A study conducted in South India reported that nearly 70% of children with CP were under 10 years of age, indicating an early onset and long-term need for multidisciplinary care [1,3,7,10].

Low birth weight, birth asphyxia, and neonatal infections remain the predominant risk factors for CP in Indian populations. The lack of widespread access to neonatal intensive care units (NICUs) and perinatal monitoring in rural regions exacerbates the risk. Children from socioeconomically disadvantaged backgrounds are more likely to present with severe forms of CP due to delayed diagnosis and insufficient intervention [1,10].




Figure 1: Worldwide and regional rates of cerebral palsy and developmental intellectual disability in children under 5 years (2019). Source: [25].




Figure 2: Global prevalence of cerebral palsy and developmental intellectual disability per 100,000 children under age 5 (2019). Source: [25].

Etiology and risk factors

The causes of CP are multifactorial, often involving hypoxic-ischemic encephalopathy, intrauterine infections, maternal health conditions, preterm birth, genetic predispositions, and neonatal complications such as intracranial hemorrhage or kernicterus. Advances in perinatal care have significantly improved survival rates for preterm and low-birth-weight infants; however, these populations remain at an increased risk for developing CP due to the vulnerability of their developing nervous system [6,18,19].

Classification of CP and functional impairments

CP is classified based on motor impairment type and the affected body regions:

- Spastic CP (70-80%): Characterized by increased muscle tone and stiffness, leading to contractures and difficulties with voluntary movement.
- Dyskinetic CP (10-15%): Marked by involuntary movements, including dystonia and choreoathetosis, due to basal ganglia dysfunction.
- Ataxic CP (5-10%): Involves impaired balance, coordination, and depth perception, typically associated with cerebellar damage.
- Mixed CP: A combination of different motor impairment types, often spasticity with dystonia [6,13,17].

The level of motor dysfunction is commonly assessed using the Gross Motor Function Classification System (GMFCS), which categorizes individuals based on their mobility and need for assistive devices. Approximately 30-50% of individuals with CP also present with cognitive impairments, epilepsy, sensory deficits, and communication difficulties, further complicating treatment strategies [13,14].

Need for comprehensive treatment approaches

The management of CP is not curative but focuses on enhancing mobility, reducing pain and spasticity, improving communication abilities, and optimizing overall quality of life. Due to the heterogeneity of CP, treatment must be individualized and multidisciplinary, involving neurologists, physiatrists, orthopedic surgeons, physical therapists, occupational therapists, speech-language pathologists, and social workers.

- Pharmacological interventions, including muscle relaxants (baclofen, botulinum toxin) and anticonvulsants, help manage spasticity and seizures.
- Rehabilitation therapies, such as physiotherapy, occupational therapy, and speech therapy, are crucial in improving motor function, daily activities, and communication.
- Surgical procedures, including orthopedic interventions and neurosurgical techniques like Selective Dorsal Rhizotomy (SDR), offer long-term benefits for patients with severe motor impairments.
- Emerging treatments, including gene therapy, stem cell therapy, and robotic-assisted rehabilitation, show promise in transforming CP management [4,11,12,14-16].

The Objective of this Review

Given the complexity of CP and its varied treatment approaches, this review aims to:

1. Analyze and categorize the various treatment modalities available for CP to provide a structured understanding of pharmacological, rehabilitative, and surgical interventions.
2. Assess the efficacy of different treatment strategies based on standardized outcome measures such as GMFCS, CPCHILD, and PEDI.
3. Explore innovative therapies and future advancements, including AI-driven rehabilitation, regenerative medicine, and precision medicine.

Review Methodology

This review synthesizes information from peer-reviewed research articles, clinical trials, and systematic analyses sourced from databases such as PubMed, Scopus, and Google Scholar. Search terms included “Cerebral Palsy Treatments”, “Rehabilitation Strategies for CP”, “Spasticity Management in CP”, and “Effectiveness of CP Interventions.” Inclusion criteria focused on evidence-based studies, clinical trials, and guidelines from reputable health organizations, while case reports and non-peer-reviewed articles were excluded.

A systematic approach was employed to categorize treatment modalities based on efficacy, clinical applicability, and impact on patient quality of life. Studies were critically evaluated for methodological rigor, sample size, and statistical significance. The findings were synthesized into key treatment categories, including pharmacological management, rehabilitation therapies, surgical interventions, speech and communication aids, and alternative treatment strategies.

Classification of cerebral palsy treatments

Pharmacological interventions

Pharmacological approaches are integral to CP management, addressing spasticity, seizures and pain.

- Muscle relaxants: Baclofen, diazepam, and botulinum toxin type A are commonly prescribed to alleviate spasticity, improve muscle flexibility, and enhance functional mobility. Baclofen can be administered orally or via an intrathecal pump for severe cases, helping to reduce hypertonia and involuntary movements [4,11,14].
- Seizure management: Many CP patients experience epilepsy, necessitating the use of anticonvulsants such as valproate, levetiracetam, and lamotrigine to control seizure activity and prevent neurological deterioration. Effective seizure control is crucial for cognitive function and overall neurodevelopmental stability [4,5,14].
- Pain management: Chronic pain is prevalent in CP due to musculoskeletal abnormalities. Nonsteroidal anti-inflammatory drugs (NSAIDs), gabapentin, and opioids are used to improve comfort and quality of life. Emerging therapies, including cannabinoids, are being investigated for their analgesic properties in CP-related pain management [20-22].

Physical and occupational therapy rehabilitation therapy plays a critical role in maintaining and improving motor function, daily activities, and independence.

- Physiotherapy: Focuses on muscle strengthening, joint flexibility, and postural control through structured exercises, stretching, and gait training. Intensive physiotherapy programs, such as constraint-induced movement therapy, have demonstrated efficacy in improving limb function in hemiplegic CP [20,21].
- Occupational therapy: Aims to enhance fine motor skills, coordination, and self-care activities such as dressing, eating, and writing. Sensory integration therapy is often incorporated to help patients process and respond to environmental stimuli more effectively [5,14].
- Assistive devices and adaptive equipment: Orthotic devices, braces, walkers, and wheelchairs help improve mobility and stability, reducing the risk of falls and joint contractures. Robotic exoskeletons and functional electrical stimulation (FES) are emerging as promising interventions to improve motor control and endurance [4,11,12,14].

Surgical interventions: Surgical procedures may be required to correct musculoskeletal abnormalities and improve functional mobility.

- Selective dorsal rhizotomy (SDR): This neurosurgical procedure selectively cuts overactive nerve roots in the spinal cord to reduce spasticity and improve voluntary movement. SDR is most effective in children with severe spastic diplegia [16,17].
- Orthopedic surgeries: Procedures such as tendon lengthening, osteotomies, and spinal fusion help manage contractures, scoliosis, and hip dislocations. These interventions aim to improve alignment, reduce pain, and enhance mobility [14,17].
- Deep brain stimulation (DBS): An experimental intervention that targets movement regulation by modulating abnormal brain activity, showing promise in cases of dyskinetic CP. DBS has been investigated in movement disorders like Parkinson's disease and is now being explored in CP to improve involuntary movement control [14,17].

Speech and communication therapy: Communication impairments are common in CP, necessitating specialized interventions.

- Augmentative and alternative communication (AAC): Devices such as communication boards, text-to-speech software, and eye-tracking systems help nonverbal patients express their needs effectively.
- Speech therapy: Focuses on improving articulation, phonation, and swallowing difficulties through targeted exercises and assistive communication tools. Swallowing therapy, including neuromuscular electrical stimulation, is beneficial for managing dysphagia [4,5,9,11].

Complementary and emerging therapies

- Acupuncture, yoga, and hydrotherapy: These modalities aim to reduce muscle stiffness, enhance relaxation, and improve motor control. Studies suggest hydrotherapy can enhance the range of motion and alleviate pain in CP patients.
- Stem cell therapy: An emerging field that investigates the potential of regenerative medicine in repairing damaged neural tissue and improving motor function in CP patients. Although promising, its clinical application remains under investigation [4,5].

Future directions and emerging innovations

- Gene therapy: Research is exploring genetic modifications to target underlying causes of CP, aiming to prevent disease progression and improve motor function.
- AI and robotics: Artificial intelligence-driven rehabilitation systems and robotic-assisted devices enhance motor learning and functional recovery by providing real-time feedback and adaptive training programs.
- Precision medicine: Personalized treatment strategies based on genetic, environmental, and clinical factors may optimize therapeutic outcomes and minimize adverse effects [4,5,12].

Conclusion

Managing CP requires a multidisciplinary approach incorporating pharmacological, rehabilitative, and surgical interventions tailored to each patient's specific needs. Continuous evaluation of treatment outcomes ensures effectiveness and promotes individualized care. The integration of novel therapies such as gene therapy, AI-driven rehabilitation, and precision medicine can revolutionize CP management, improving mobility, communication, and overall quality of life for affected individuals [4,11,12,14,15].

Bibliography

1. Jindal P, *et al.* "Treatment and rehabilitation of children with cerebral palsy in India: a scoping review". *Developmental Medicine and Child Neurology* 61.9 (2019): 1050-1060.
2. Gowda VK. "Recent advances in cerebral palsy". *Karnataka Paediatric Journal* 35.1 (2020): 4-18.
3. Shukla D. "Socio-demographic and clinical profile of pediatric patients with cerebral palsy in Gujarat, India". *Bulletin of Faculty of Physical Therapy* 27 (2022): 19.
4. Kumar R, *et al.* "Recent advancements in interventions for cerebral palsy - A review". *Journal of Clinical Orthopaedics and Trauma* 24 (2023): 101746.
5. India State-Level Disease Burden Initiative Neurological Disorders Collaborators. "The burden of neurological disorders across the states of India: the Global Burden of Disease Study 1990-2019". *The Lancet Global Health* 9.8 (2021): e1129-e1144.

6. Sankar C and Mundkur N. "Cerebral palsy-definition, classification, etiology and early diagnosis". *Indian Journal of Pediatrics* 72.10 (2005): 865-868.
7. Arora RS, *et al.* "Prevalence of cerebral palsy in Indian children: a systematic review and meta-analysis". *Indian Journal of Pediatrics* 87.11 (2020): 976-981.
8. Khanna S, *et al.* "Neurodevelopmental treatment in children with cerebral palsy: a review of the literature". *Cureus* 15.12 (2023): e50389.
9. Pani SK, *et al.* "Case report on cerebral palsy with Ayurvedic treatment protocol". *Journal of Pharmaceutical Research International* 33.43A (2021): 47-50.
10. Ghosh S and Dey SK. "Quality of life of children with cerebral palsy: evidence from Assam, India". *Disability and Health Journal* 17.2 (2024): 101182.
11. Indian Academy of Pediatrics. "Cerebral palsy". In: Kamath SS, Ratageri VH, eds. IAP Standard Treatment Guidelines (2022): 188-193.
12. Patel DR, *et al.* "Cerebral palsy in children: a clinical overview". *Translational Pediatrics* 9.1 (2020): S125-S135.
13. Brunstrom-Hernandez J. "The gross motor function classification system (GMFCS) explained". *Developmental Medicine and Child Neurology* 59.1 (2017): 79-80.
14. Graham D, *et al.* "The effect of botulinum toxin A on walking in children with cerebral palsy: a randomized controlled trial". *Developmental Medicine and Child Neurology* 50.10 (2008): 719-725.
15. Novak I, *et al.* "State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy". *Current Neurology and Neuroscience Reports* 20.2 (2020): 3.
16. Park TS and Owen JH. "Surgical management of spasticity in cerebral palsy". *Seminars in Pediatric Neurology* 9.2 (2002): 81-87.
17. Tedroff K, *et al.* "Selective dorsal rhizotomy in children with cerebral palsy: a 10-year follow-up study". *Developmental Medicine and Child Neurology* 57.5 (2015): 484-490.
18. Delgado MR and Albright AL. "Movement disorders in children: definitions, classifications, and grading schemes". *Journal of Child Neurology* 18.1 (2003): S1-S8.
19. Christensen E and Melchior JC. "Risk factors for cerebral palsy in children". *Early Human Development* 34.1-2 (1993): 57-72.
20. Reddiough DS and Collins KJ. "The epidemiology and causes of cerebral palsy". *Australian Journal of Physiotherapy* 49.1 (2003): 7-12.
21. Anttila H, *et al.* "Effectiveness of physical therapy interventions for children with cerebral palsy: a systematic review". *Clinical Rehabilitation* 22.9 (2008): 878-887.
22. Fehlings D, *et al.* "A systematic review of the effectiveness of exercise programs for children with cerebral palsy: the state of the evidence". *Developmental Medicine and Child Neurology* 54.6 (2012): 499-505.
23. Beckung E, *et al.* "Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers". *Developmental Medicine and Child Neurology* 49.8 (2007): 521-526.

24. Himmelmann K., *et al.* "The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995-1998". *Acta Paediatrica* 94.3 (2005): 287-294.
25. Bolajoko O Olusanya., *et al.* "Cerebral palsy and developmental intellectual disability in children younger than 5 years: Findings from the GBD-WHO Rehabilitation Database 2019". *Frontiers in Public Health* 10 (2022).

Volume 13 Issue 5 May 2025

©All rights reserved by Kabra Vinay S., *et al.*